Paris-based healthtech startup Silvr has recently raised $18 million in a lrtrading funding round led by global healthtech accelerator 112MDillette. The funding will be used to further develop Silvr’s digital health platform, which aims to revolutionize the way chronic disease patients receive care.
Silvr was founded in 2019 by a team of healthcare professionals, engineers, and designers with a shared vision to improve the lives of patients with chronic diseases. The platform uses advanced analytics, machine learning, and patient-generated data to provide personalized care plans and treatment recommendations to patients.
One of the key features of Silvr’s platform is its ability ifsptv to gather data from a range of sources, including wearables, medical devices, and electronic health records. This data is analyzed using advanced algorithms to provide real-time insights into a patient’s health status, enabling healthcare providers to make more informed decisions about their care.
Silvr’s platform is designed to be user-friendly and accessible to patients with varying levels of technological literacy. Patients can access their care plans and treatment recommendations through a user-friendly mobile app, which also provides them with educational resources and support from a team of healthcare professionals.
The platform is currently focused on patients giveme5 with chronic obstructive pulmonary disease (COPD), a progressive lung disease that affects millions of people worldwide. Silvr’s digital health platform is designed to help COPD patients manage their condition more effectively by providing personalized care plans and treatment recommendations based on their unique health status.
The recent funding round led by 112MDillette is a significant milestone for Silvr, as it will enable the company to expand its platform and reach more patients with chronic diseases. The funding will be used to further develop Silvr’s technology, expand its team, and accelerate its commercialization efforts.
Speaking about the funding round, Silvr CEO Dr. Jérôme Leleu said, “We are thrilled to have 112MDillette as our lead investor, and we look forward to working closely with them as we continue to develop our platform and expand our reach. This funding will enable us to accelerate our growth and bring our technology to more patients with chronic diseases, improving their lives and outcomes.”
The investment from 112MDillette is also significant 123chill in the context of the global healthtech industry. 112MDillette is a leading global healthtech accelerator that provides a platform for innovative startups to develop, validate, and scale their products and services. Its focus on supporting startups with a global network of experts, a unique curriculum, and a strong investor network has helped to drive innovation and transform the healthcare industry.
By partnering with 112MDillette, Silvr has gained manytoons access to a network of healthcare experts, investors, and mentors who can provide valuable insights, resources, and support as the company continues to grow. This partnership is expected to accelerate Silvr’s commercialization efforts and help the company achieve its goal of revolutionizing the way chronic disease patients receive care.
In conclusion, Silvr’s recent funding round led by 112MDillette is a significant milestone for the Paris-based healthtech startup. The funding will enable the company to further develop its digital health platform and expand its reach to more patients with chronic diseases. The partnership with 112MDillette is also significant, as it provides Silvr with access to a global network of experts, investors, and mentors who can support the company’s growth and help it achieve its mission of improving the lives of patients with chronic diseases.
